160976-02-3

Basic information

• Product Name: 4-Bromo-2,6-difluoroiodobenzene
• Synonyms: 4-BROMO-2,6 DIFLUORO-1-IODOBENZENE;4-BROMO-2,6-DIFLUOROIODOBENZENE;2,6-DIFLUORO-4-BROMOIODOBENZENE;1-BROMO-3,5-DIFLUORO-4-IODOBENZENE;Bromodifluoroiodobenzene;5-Bromo-1,3-difluoro-2-iodobenzene
• CAS NO: 160976-02-3
• Molecular Formula: C₆H₂BrF₂I
• Molecular Weight: 318.89
• Mol File: 160976-02-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 40-41°C
• Boiling Point: 236.057 °C at 760 mmHg
• Flash Point: 96.564 °C
• Appearance: /
• Density: 2.343 g/cm³
• Vapor Pressure: 0.0742mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 4-Bromo-2,6-difluoroiodobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-2,6-difluoroiodobenzene(160976-02-3)
• EPA Substance Registry System: 4-Bromo-2,6-difluoroiodobenzene(160976-02-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 160976-02-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-white to light brown solid

InChI:InChI=1/C6H2BrF2I/c7-3-1-4(8)6(10)5(9)2-3/h1-2H

Upstream product

• 461-96-1 3,5-difluorobromobenzene 

Downstream Products

• 1400706-90-2 5-(4-brom-2,6-difluoro-phenyl)-oxazole 
• 1400706-91-3 3,5-difluoro-4-oxazol-5-yl-benzoic acid methyl ester 
• 1400706-92-4 3,5-difluoro-4-oxazol-5-yl-benzoic acid 

Relevant articles and documents

Utilising Sodium-Mediated Ferration for Regioselective Functionalisation of Fluoroarenes via C?H and C?F Bond Activations

Pairing iron bis(amide) Fe(HMDS)2 with Na(HMDS) to form new sodium ferrate base [(dioxane)0.5?NaFe(HMDS)3] (1) enables regioselective mono and di-ferration (via direct Fe?H exchange) of a wide range of fluoroaromatic substrates under mild reaction conditions. Trapping of several ferrated intermediates has provided key insight into how synchronised Na/Fe cooperation operates in these transformations. Furthermore, using excess 1 at 80 °C switches on a remarkable cascade process inducing the collective twofold C?H/threefold C?F bond activations, where each C?H bond is transformed to a C?Fe bond whereas each C?F bond is transformed into a C?N bond.

N-(4-biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: Metabolic robustness due to fluorine substitution?

3,3′,5,5′- And 2,2′,6,6′-tetrafluoro-substituted 1-[(1,1′-biphenyl]-4-yl)methyl]-1H-imidazoles were synthesized as inhibitors of 17α-hydroxylase-C17,20-lyase (P450 17, CYP 17). P450 17 is the key enzyme of androgen biosynthesis. Its inhibition is a novel